SEC Form 10-Q filed by NKGen Biotech Inc.
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U
SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th
SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today issued the following statement in response to recent shareholder inquiries regarding its current trading status on the OTC Expert Market and the display of a $0.00 common stock, $0.0001 par value per share (the "Common Stock"), price on certain financial websites. The appearance of a $0.00 Common Stock price does not reflect the actual value of the Company or its Common Stock. This figure results from the l
10-Q - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U
SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator ("PI") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orl
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026.Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song. SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK")
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease, expect to initiate Phase I/IIa by year end – SNK02 Phase I allogeneic clinical program continues to progress; anticipated preliminary solid tumor data readout and IND filing for Parkinson's Disease in 1Q24 SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NASDAQ:NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the
SC 13G - NKGen Biotech, Inc. (0001845459) (Subject)
SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)